EAU 2018

EAU 2018: Bladder Cancer: Immediate and Late Complications Open Radical Cystectomy

Copenhagen, Denmark (UroToday.com) The gold standard for managing muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy followed by radical cystectomy (RC). The majority of RCs are still performed via an open approach, and Dr. Georgios Garkis presented on immediate and late complications following RC. 

EAU 2018: Does Renal Biopsy Make Sense in View of Tumor Heterogeneity?

Copenhagen, Denmark (UroToday.com)  Dr. Holger Moch, a pathologist from University Hospital Zurich presented a discussion regarding the role of renal biopsy from the pathologist’s perspective. Tumor heterogeneity, in terms of morphology, grade and molecular characteristics, is well recognized in renal tumors, including small renal masses. Dr. Moch started by highlighting that the ASCO guidelines for small renal masses [1] state that partial nephrectomy is the standard treatment for small renal masses, and that all patients with small renal masses should be considered for renal tumor biopsy when the results may alter management.

EAU 2018: How Should I Manage a Patient with Tumour Recurrence Despite Adequate BCG?

Copenhagen, Denmark (UroToday.com)  This is one of a series of case-based debates. Each is set up as follows: 2 min case-presentation, 5-min discussant presentation (two sides of the debate, discussion), summary 2 minutes. This series was arranged by Dr. Kamat, Dr. Grossman, and Dr. Stenzl.

EAU 2018: Holmium Laser Enucleation of the Prostate is Effective and Safe in all Prostate Sizes

Copenhagen, Denmark (UroToday.com) Danielle Whiting, clinical urology trainee from the Tunbridge Wells NHS Trust in Maidstone, United Kingdom, described her study on the application of Holmium laser enucleation of the prostate (HoLEP) in several types of lower urinary tract symptoms (LUTS). Miss Whiting’s stance on the procedure was that HoLEP is effective and safe in small and large prostate sizes with men suffering from these symptoms. In regard to larger prostate sizes, surgeons most often use HoLEP as their gold standard procedure while favoring transurethral resection of the prostate (TURP) for smaller prostatic conditions. In this study, the outcomes and complications from a single center were sought to determine whether HoLEP was in fact beneficial for small sized prostates in addition to large sized prostates. 

EAU 2018: Risk Factors of Short-Term Surgical Retreatment After Greenlight Laser Therapy for Benign Prostate Hyperplasia: A Multi-Institutional Analysis

Copenhagen, Denmark (UroToday.com) Dr. I. Ouzaid, a clinical urologist from the Bichat Hospital in Paris, France, presented his center’s findings on the risk factors of short-term surgical reintervention of obstruction after Greenlight™ photoselective vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH).

EAU 2018: Oncologic Outcomes After Robot-Assisted Radical Cystectomy

Copenhagen, Denmark (UroToday.com)  Dr. Collins provided a discussion highlighting the oncologic outcomes after robot-assisted radical cystectomy (RARC). Dr. Collins started by highlighting indications for robotic-assisted radical cystectomy: 

EAU 2018: Perioperative Major Acute Cardiovascular Events after 180-Watt Green Light Laser Photoselective Vaporization

Copenhagen, Denmark (UroToday.com)  Dr. M. Marchioni, clinical urologist from the Università Degli Studi in Chieti, Italy, presented a cohort of prostate resection patients who are at a high bleeding risk due to the inability of anticoagulant or antiplatelet drugs could not be suspended. In these patients, the gold standard treatement to reduce blood loss is 180-Watt Green Light (180-W GL) laser photoselective vaporization (PVP).